This observation indeed supports our in vitro data indicating that GABBR2 could induce CDDP resistance in bladder cancer, although only a portion of patients in the database cohort may have undergone CDDP-based chemotherapy. This evidence concerns the gene GABBR2 and urinary bladder carcinoma.